<SEC-DOCUMENT>0001193125-25-316569.txt : 20251211
<SEC-HEADER>0001193125-25-316569.hdr.sgml : 20251211
<ACCEPTANCE-DATETIME>20251211205221
ACCESSION NUMBER:		0001193125-25-316569
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251211
DATE AS OF CHANGE:		20251211

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Opus Genetics, Inc.
		CENTRAL INDEX KEY:			0001228627
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				113516358
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-79996
		FILM NUMBER:		251566338

	BUSINESS ADDRESS:	
		STREET 1:		8 DAVIS DRIVE
		STREET 2:		SUITE 220
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		248-681-9815

	MAIL ADDRESS:	
		STREET 1:		8 DAVIS DRIVE
		STREET 2:		SUITE 220
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ocuphire Pharma, Inc.
		DATE OF NAME CHANGE:	20201109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REXAHN PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20050516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORPORATE ROAD SHOW DOT COM INC
		DATE OF NAME CHANGE:	20030423

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Foundation Fighting Blindness Retinal Degeneration Fund
		CENTRAL INDEX KEY:			0002042266
		ORGANIZATION NAME:           	
		EIN:				450524687
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		223 S. WEST STREET, SUITE 900
		CITY:			RALEIGH
		STATE:			NC
		ZIP:			27603
		BUSINESS PHONE:		800-683-5555

	MAIL ADDRESS:	
		STREET 1:		223 S. WEST STREET, SUITE 900
		CITY:			RALEIGH
		STATE:			NC
		ZIP:			27603
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002042266</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <dateOfEvent>12/09/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001228627</issuerCIK>
        <issuerCUSIP>67577R102</issuerCUSIP>
        <issuerName>Opus Genetics, Inc.</issuerName>
        <address>
          <street1 xmlns="http://www.sec.gov/edgar/common">8 Davis Drive, Suite 220</street1>
          <city xmlns="http://www.sec.gov/edgar/common">Durham</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">NC</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">27713</zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Russell Kelley, Managing Dir.</personName>
          <personPhoneNum>(919) 610-2064</personPhoneNum>
          <personAddress>
            <street1 xmlns="http://www.sec.gov/edgar/common">Foundation Fighting Blindness RD Fund</street1>
            <street2 xmlns="http://www.sec.gov/edgar/common">223 S. West Street, Suite 900</street2>
            <city xmlns="http://www.sec.gov/edgar/common">Raleigh</city>
            <stateOrCountry xmlns="http://www.sec.gov/edgar/common">NC</stateOrCountry>
            <zipCode xmlns="http://www.sec.gov/edgar/common">27603</zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002042266</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Foundation Fighting Blindness Retinal Degeneration Fund</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>5492171</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>5492171</sharedDispositivePower>
        <aggregateAmountOwned>5492171</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>8.0</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>Percent of class represented in Row (11) is based on 68,964,208 shares of common stock, $0.0001 par value per share (the "Common Stock") of Opus Genetics, Inc., a Delaware corporation (the "Issuer") outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 12, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0002042532</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Foundation Fighting Blindness, Inc.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>MD</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>5492171</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>5492171</sharedDispositivePower>
        <aggregateAmountOwned>5492171</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>8.0</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>Percent of class represented in Row (11) is based on 68,964,208 shares of the Issuer's Common Stock outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, $0.0001 par value per share</securityTitle>
        <issuerName>Opus Genetics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">8 Davis Drive, Suite 220</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 200</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Durham</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">NC</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">27713</zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 2 on Schedule 13D amends the statement on Schedule 13D, dated October 29, 2024, which was amended on Schedule 13D/A dated March 6, 2025, which relates to the Common Stock of the Issuer, filed by the Reporting Persons. This Amendment No. 2 on Schedule 13D is being filed to show the change in percentage of beneficial ownership held by the Reporting Persons as a result of selling shares of the Issuer's Common Stock on December 9, 2025.</commentText>
      </item1>
      <item5>
        <percentageOfClassSecurities>5492171 - 8%</percentageOfClassSecurities>
        <numberOfShares>5492171</numberOfShares>
        <transactionDesc>Reference is made to the Form 4 filed by the Reporting Persons on December 11, 2025 with the SEC pursuant to Section 16 of the Act and is available on the SEC's website at www.sec.gov.  The information reported in the filings are expressly incorporated herein.</transactionDesc>
        <date5PercentOwnership>Not Applicable.</date5PercentOwnership>
      </item5>
      <item7>
        <filedExhibits>Exhibit 1 - Agreement and Plan of Merger, dated October 22, 2024, by an among Ocuphire Pharma, Inc., Orange Merger Sub I, Inc., Orange Merger Sub II, LLC, and Opus Genetics Inc. (incorporated by reference to Exhibit 2.1 of the Issuer's Current Report on Form 8-K filed with the SEC on October 22, 2024).

Exhibit 2 - Certificate of Designations of the Series A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Issuer's Current Report on Form 8-K filed with the SEC on October 22, 2024).

Exhibit 3 - Form of Lock-Up Agreement (included as Exhibit B to the Agreement and Plan of Merger filed as Exhibit 2.1 to the Issuer's current report on Form 8-K as filed with the SEC on October 22, 2024 and incorporated herein by reference).

Exhibit 4 - Form of Registration Rights Agreement (included as Exhibit F to the Agreement and Plan of Merger filed as Exhibit 2.1 to the Issuer's current report on Form 8-K as filed with the SEC on October 22, 2024 and incorporated herein by reference).

Exhibit 5 - Joint Filing Agreement by and between the Reporting Persons (incorporated by reference to Exhibit 5 to the Schedule 13D/A as filed by the Reporting Persons with the SEC on May 6, 2025).</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Foundation Fighting Blindness Retinal Degeneration Fund</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Russell Kelley</signature>
          <title>Russell Kelley, Managing Director</title>
          <date>12/11/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Foundation Fighting Blindness, Inc.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Jason Menzo</signature>
          <title>Jason Menzo, Chief Executive Officer</title>
          <date>12/11/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
